What are the contraindications to using cisplatin as neoadjuvant chemotherapy for bladder cancer?

Contraindications to Cisplatin-Based Neoadjuvant Chemotherapy in Bladder Cancer

Patients with pre-existing renal impairment, myelosuppression, hearing impairment, or a history of allergic reactions to platinum compounds are absolutely contraindicated from receiving cisplatin-based neoadjuvant chemotherapy for bladder cancer. 1

Absolute Contraindications (FDA-Labeled)

The FDA drug label for cisplatin explicitly lists the following as absolute contraindications 1:

• Pre-existing renal impairment - Cisplatin produces cumulative nephrotoxicity and should not be used in patients with baseline renal dysfunction 1
• Myelosuppression - Patients with existing bone marrow suppression cannot receive cisplatin 1
• Hearing impairment - Pre-existing ototoxicity contraindicates cisplatin use, as the drug commonly causes cumulative ototoxicity that may be severe 1
• History of allergic reactions to cisplatin or other platinum-containing compounds 1

Clinical Contraindications from Guidelines

Beyond the FDA absolute contraindications, multiple high-quality guidelines identify additional clinical scenarios where cisplatin-based NACT should not be given 2:

Renal Function Criteria

• Creatinine clearance <60 mL/min is the standard threshold for cisplatin ineligibility 2
• Patients should have estimated GFR assessed before determining cisplatin eligibility 2
• For borderline renal function, split-dose cisplatin administration may be considered (category 2B), though relative efficacy remains undefined 2

Performance Status and Comorbidities

• Poor performance status (WHO performance status ≥2 or ECOG ≥2) 2
• Neuropathy ≥grade 2 - Pre-existing peripheral neuropathy contraindicates cisplatin, as the drug causes potentially irreversible neuropathies 2
• Hearing loss ≥grade 2 2
• NYHA Class III-IV heart failure or significant cardiac comorbidities 2

Important Clinical Considerations

If neoadjuvant cisplatin-based chemotherapy cannot be given due to contraindications, neoadjuvant chemotherapy is not recommended - the NCCN guidelines explicitly state this, as carboplatin has not demonstrated a survival benefit and should not be substituted for cisplatin in the perioperative setting 2. This represents a critical practice point: approximately 40% of patients are not fit enough to receive cisplatin-containing therapy 2.

Alternative Approaches for Cisplatin-Ineligible Patients

For patients with metastatic disease who are cisplatin-ineligible, the ESMO guidelines recommend 2:

• Gemcitabine-carboplatin for PD-L1-unknown or -negative patients
• Atezolizumab or pembrolizumab for PD-L1-positive patients

However, these alternatives have not been validated in the neoadjuvant setting with survival data comparable to cisplatin-based regimens 3, 4.

Common Pitfalls to Avoid

• Do not substitute carboplatin for cisplatin in the neoadjuvant/perioperative setting - this is explicitly contraindicated by multiple guidelines as it has not demonstrated survival benefit 2
• Do not use "textbook" definitions of cisplatin ineligibility too restrictively - these may exclude up to 50% of patients who might tolerate therapy with careful monitoring 4
• Elderly patients require special consideration - they may be more susceptible to both nephrotoxicity and peripheral neuropathy 1
• Audiometric testing is mandatory prior to initiating therapy and before each subsequent dose, particularly in pediatric patients 1